Orthocell has received regulatory approval from Singapore’s Health Sciences Authority (HSA) for its market leading dental guided bone regeneration product, Striate+\u2122.<\/p>\n
This approval complements existing approvals in the US, Europe\/UK, Australia, New Zealand and Canada, and paves the way for further expansion into other ASEAN markets.<\/p>\n
BioHorizons, our global marketing and distribution partner, is already well established in Singapore, which will facilitate a fast transition to first sales in this key market.<\/p>\n
Orthocell CEO and MD, Paul Anderson, said:<\/p>\n
\u201cWe are delighted to receive Singaporean regulatory approval for Striate+ in this important regional gateway market. This approval provides additional validation of Orthocell\u2019s high-quality products, manufacturing processes, and quality systems. Moreover, it enhances our ability to drive revenue growth as our distribution partner expands into global markets.\u201d<\/p>\n